Liu Lihong, Wang Weiming, Matz Julie, Ye Chaobaihui, Bracq Lucie, Delon Jerome, Kimata Jason T, Chen Zhiwei, Benichou Serge, Zhou Paul
Unit of Anti-Viral Immunity and Genetic Therapy, Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.
Institut Cochin-INSERM U1016-CNRS UMR 8104-University Paris Descartes, Paris, France.
J Virol. 2016 Nov 14;90(23):10642-10659. doi: 10.1128/JVI.01559-16. Print 2016 Dec 1.
The variable regions (VHHs) of two heavy chain-only antibodies, JM2 and JM4, from llamas that have been immunized with a trimeric gp140 bound to a CD4 mimic have been recently isolated (here referred to as VHH JM2 and VHH JM4, respectively). JM2 binds the CD4-binding site of gp120 and neutralizes HIV-1 strains from subtypes B, C, and G. JM4 binds gp120 and neutralizes HIV-1 strains from subtypes A, B, C, A/E, and G in a CD4-dependent manner. In the present study, we constructed glycosylphosphatidylinositol (GPI)-anchored VHH JM2 and JM4 along with an E4 control and transduced them into human CD4 cell lines and primary CD4 T cells. We report that by genetically linking the VHHs with a GPI attachment signal, VHHs are targeted to the lipid rafts of the plasma membranes. Expression of GPI-VHH JM4, but not GPI-VHH E4 and JM2, on the surface of transduced TZM.bl cells potently neutralizes multiple subtypes of HIV-1 isolates, including tier 2 or 3 strains, transmitted founders, quasispecies, and soluble single domain antibody (sdAb) JM4-resistant viruses. Moreover, transduction of CEMss-CCR5 cells with GPI-VHH JM4, but not with GPI-VHH E4, confers resistance to both cell-free and T cell-T cell transmission of HIV-1 and HIV-1 envelope-mediated fusion. Finally, GPI-VHH JM4-transduced human primary CD4 T cells efficiently resist both cell-free and T cell-T cell transmission of HIV-1. Thus, we conclude that VHH JM4, when targeted to the lipid rafts of the plasma membrane, efficiently neutralizes HIV-1 infection via both cell-free and T cell-T cell transmission. Our findings should have important implications for GPI-anchored antibody-based therapy against HIV-1.
Lipid rafts are specialized dynamic microdomains of the plasma membrane and have been shown to be gateways for HIV-1 budding as well as entry into T cells and macrophages. In nature, many glycosylphosphatidylinositol (GPI)-anchored proteins localize in the lipid rafts. In the present study, we developed GPI-anchored variable regions (VHHs) of two heavy chain-only antibodies, JM2 and JM4, from immunized llamas. We show that by genetically linking the VHHs with a GPI attachment signal, VHHs are targeted to the lipid rafts of the plasma membranes. GPI-VHH JM4, but not GPI-VHH JM2, in transduced CD4 cell lines and human primary CD4 T cells not only efficiently blocks diverse HIV-1 strains, including tier 2 or 3 strains, transmitted founders, quasispecies, and soluble sdAb JM4-resistant strains, but also efficiently interferes T cell-T cell transmissions of HIV-1 and HIV-1 envelope-mediated fusion. Our findings should have important implications in GPI-anchored antibody-based therapy against HIV-1.
最近从用结合了CD4模拟物的三聚体gp140免疫的羊驼中分离出了两种仅重链抗体JM2和JM4的可变区(VHHs)(在此分别称为VHH JM2和VHH JM4)。JM2结合gp120的CD4结合位点并中和B、C和G亚型的HIV-1毒株。JM4以CD4依赖的方式结合gp120并中和A、B、C、A/E和G亚型的HIV-1毒株。在本研究中,我们构建了糖基磷脂酰肌醇(GPI)锚定的VHH JM2和JM4以及E4对照,并将它们转导到人CD4细胞系和原代CD4 T细胞中。我们报告说,通过将VHHs与GPI附着信号进行基因连接,VHHs被靶向到质膜的脂筏。在转导的TZM.bl细胞表面表达GPI-VHH JM4,但不表达GPI-VHH E4和JM2,可有效中和多种亚型的HIV-1分离株,包括2级或3级毒株、传播奠基者、准种以及对可溶性单域抗体(sdAb)JM4耐药的病毒。此外,用GPI-VHH JM4而非GPI-VHH E4转导CEMss-CCR5细胞,可赋予其对HIV-1的无细胞传播和T细胞-T细胞传播以及HIV-1包膜介导的融合的抗性。最后,用GPI-VHH JM4转导的人原代CD4 T细胞有效抵抗HIV-1的无细胞传播和T细胞-T细胞传播。因此,我们得出结论,当VHH JM4靶向到质膜的脂筏时,它可通过无细胞传播和T细胞-T细胞传播有效中和HIV-1感染。我们的发现对于基于GPI锚定抗体的抗HIV-1治疗应该具有重要意义。
脂筏是质膜的特殊动态微区,已被证明是HIV-1出芽以及进入T细胞和巨噬细胞的通道。在自然界中,许多糖基磷脂酰肌醇(GPI)锚定蛋白定位于脂筏。在本研究中,我们开发了来自免疫羊驼的两种仅重链抗体JM2和JM4的GPI锚定可变区(VHHs)。我们表明,通过将VHHs与GPI附着信号进行基因连接,VHHs被靶向到质膜的脂筏。在转导的CD4细胞系和人原代CD4 T细胞中,GPI-VHH JM4而非GPI-VHH JM2不仅有效阻断多种HIV-1毒株,包括2级或3级毒株、传播奠基者、准种以及对可溶性sdAb JM4耐药的毒株,而且有效干扰HIV-1的T细胞-T细胞传播和HIV-1包膜介导的融合。我们的发现对于基于GPI锚定抗体的抗HIV-1治疗应该具有重要意义。